The combination of Opdivo plus Yervoy is already established as a second-line treatment for patients with advanced hepatocellular carcinoma. Two Bristol Myers Squibb products, Opdivo (nivolumab) plus Yervoy (ipilimumab), have been accepted in tandem with one another as a potential first-line treatment for adult patients with unresectable hepatocellular carcinoma (HCC). A press release from Bristol Myers Squibb on Aug. 21, 2024 said that FDA had accepted the company’s supplemental Biologics License Application based on results from a Phase III trial (CheckMate -9DW), and set a Prescription Drug User Fee Act goal date of Apr. 21, 2025 (1).

FDA Accepts Bristol Myers Squibb Application for Unresectable Hepatocellular Carcinoma First-Line Treatment

Cancer Health

FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.

FDA Approves New Targeted Therapy for Brain Cancer

The Food and Drug Administration (FDA) has approved three new immunotherapy options for people with advanced endometrial cancer. The approvals are for drugs called immune checkpoint inhibitors. The first approval, announced on June 14, is for durvalumab (Imfinzi) given in combination with chemotherapy to treat people with advanced endometrial cancer...

More Immunotherapy Options Approved for Treating Endometrial Cancer

The combination treatment involves administering Imfinzi with neoadjuvant chemotherapy for non-small cell lung cancer before surgery and as monotherapy post-surgery. The FDA has approved AstraZeneca’s Imfinzi in combination with chemotherapy for treating adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) without epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Administration of Imfinzi with neoadjuvant chemotherapy is performed before surgery and as monotherapy post-surgery. The approval is based on positive results from the AEGEAN trial.1.

FDA Approves AstraZeneca’s Imfinzi in Combination with Chemotherapy for Resectable Early-Stage Non-Small Cell Lung Cancer

Reuters

(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge for AstraZeneca's blockbuster drug Tagrisso.

J&J's chemotherapy-free treatment for lung cancer gets US approval

The Marijuana Herald

The Marijuana Herald - Marijuana news and information
A new study published in the Journal of Clinical Oncology reveals that marijuana capsules containing both tetrahydrocannabinol (THC) and cannabidiol (CBD) significantly reduces chemotherapy-induced nausea and vomiting in patients who have not responded to standard antiemetic treatments. This randomized, placebo-controlled, phase II/III trial, conducted across 19 hospitals and universities in Australia, is one of the … 
Continue reading
The post Clinical Trial Finds Marijuana Capsules Effective in Reducing Chemotherapy-Induced Nausea and Vomiting appeared first on The Marijuana Herald.

Clinical Trial Finds Marijuana Capsules Effective in Reducing Chemotherapy-Induced Nausea and Vomiting

Health

Medically reviewed by Christopher Lee, MDMedically reviewed by Christopher Lee, MDHeart cancer develops when abnormal cells in the heart muscle or surrounding tissues grow uncontrollably, forming a malignant (cancerous) tumor. Cancerous heart tumors (known as cardiac sarcomas) are extremely rare, accounting for less than 0.028% of all cancer diagnoses annually.  Secondary heart cancer is when cancer cells metastasize (spread) to the heart from a tumor that started in nearby organs or body tissues. Secondary heart cancer is about 30 to 50 times more common than primary heart cancer. However, it is still rare, affecting approximately 10% of people with lung cancer,...

Signs and Symptoms of Heart Cancer

Healthline

R-ICE is a treatment for non-Hodgkin's and Hodgkin's lymphoma. It combines four chemotherapy drugs that kill cancer cells and is often used prior to a stem cell transplant. Learn more.

What Is the R-ICE Chemotherapy Protocol?

SurvivorNet

Discover how precision medicine and immunotherapy are transforming cancer treatment by utilizing genetic profiling and advanced sequencing techniques to provide personalized, targeted care with fewer side effects and improved outcomes.

Tailoring Cancer Treatment to the Patient: The Importance of Biomarker Testing in Precision Medicine

Researchers have demonstrated that adding metastasis-directed radiation therapy to standard-of-care chemotherapy may improve progression-free survival in patients with oligometastatic pancreatic cancer, according to a recent study published by Ludmir et al in the Journal of Clinical Oncology and previously presented at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 603). Background.

Metastasis-Directed Radiation Therapy Plus Chemotherapy in Oligometastatic Pancreatic Cancer

Medically reviewed by Marla Anderson, MDMedically reviewed by Marla Anderson, MDNon-small cell lung cancer (NSCLC) is a type of cancer that begins in the tissues of the lungs. About 80-85% of all lung cancer cases in the United States are classified as NSCLC. NSCLC occurs when the cells that line the surface of the lung airways change and mutate. When these abnormal cells rapidly divide and multiply, they lead to cancer. The most common cause of NSCLC is smoking, with about 90% of lung cancer cases being related to tobacco smoke exposure. It is possible to be diagnosed with NSCLC if you...

What Causes Non-Small Cell Lung Cancer (NSCLC)?

While definitions differ between regions, countries, and agencies, the National Cancer Institute defines rare cancers as those diagnosed in less than fifteen per 100,000 people annually. These malignancies, as a group, pose unique clinical challenges. Research becomes difficult because the number of cases of any particular rare cancer remains low. These factors have led to inadequate strategies for diagnosing, treating, and developing preventative measures for many rare cancers.

Rare Cancers Linked to More Anxiety and Depression than Common Cancers

Small cell lung cancer (SCLC) is a fast-growing cancer that develops in cells within the lung. A range of medical tests and procedures are available to help doctors diagnose SCLC and create an appropriate treatment plan. Lung cancer is a complex disease comprising various subtypes. A person who receives a...

How do doctors diagnose small cell lung cancer?

The Healthy 

The thyroid is a small, butterfly-shaped gland nestled at the front of the neck just beneath the skin, and plays an essential role in the body’s overall function. It is responsible for producing and releasing hormones that regulate metabolism, energy levels, and body temperature. When the thyroid isn’t functioning well or develops cancer, it can have widespread effects on throughout the body.

“Here’s How I Knew I Had Thyroid Cancer”: One Patient’s Story When Emotional & Hormonal Symptoms Crept Up

Contributors represent independent, third-party users who have joined our contributor program and self-verified their accounts. They have also demonstrated their experience writing hard news for other outlets. Contributors are expected, like all users, to adhere to our Community Standards.

contributor

Chicago Star Media

(BPT) - Julio, a 49-year-old engineer and avid runner, discovered an alarming sign of trouble right after completing a half-marathon: blood in his urine. He promptly consulted a doctor, which led to a bladder cancer diagnosis. Specifically, Julio had low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), a type known for its tendency to recur.

From bladder cancer to running half marathons: One patient’s journey

Chemotherapy is a type of cancer treatment that uses medications to kill fast-growing cancer cells. Depression may be one of the possible side effects of chemotherapy. Chemotherapy medications travel through the body and can mistakenly attack and damage healthy cells. This can leave a person with several side effects, which can be painful, change a person’s appearance, and affect their mood.

Chemotherapy and depression: Is there a connection?

GDANSK (Reuters) - BioNTech on Monday said the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on an early stage study of its experimental cancer drug.

BioNTech says FDA lifts partial hold on its cancer drug trial

Acute clinical events with stable MRI were more likely among patients with multiple sclerosis who had longer disease duration, received highly effective disease-modifying therapies, and who presented with fatigue. This article was originally published on NeurologyLive®. In a new multicenter observational cohort study published in JAMA Neurology, approximately one-fourth...

Stable MRI in Multiple Sclerosis Reveals Relapses as Acute Clinical Events

In preparation for a family member’s wedding, I purchased a new bra and protheses and felt like a princess by doing so. As a breast cancer survivor who endured a mastectomy, I’ve done my time wearing prosthesis. I wore them for years until I couldn’t wear them anymore. They were hot and heavy, and I didn’t really like the way they looked. Did I really want to be that big?So, I threw them all away and decided to go au naturel.

Feeling Like Cinderella Again After Cancer

The first FDA-approved systemic therapy may be beneficial to patients with low-grade astrocytoma or oligodendroglioma with IDH1 or 2 mutations. The recent Food and Drug Administration (FDA) approval of Voranigo (vorasidenib) is “now becoming part of standard of care option” for patients with slow-growing grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, an expert told CURE®.

Voranigo for Astrocytoma or Oligodendroglioma an ‘Important Step Forward’

NewsBreak

6 FDA Cancer Approvals from August 2024

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved. During the summer of 2024, the Food and Drug...

6 FDA Cancer Approvals from August 2024

Comments / 0